Table 2.

Recurrent free survival rates and median time to recurrence during 6-year of follow-up (Kaplan–Meier method) of breast cancer patients, Black Lion Specialized Hospital, Addis Ababa, Ethiopia in 2018 (n = 588)

Characteristic	Median time to recurrence and 95% CI	6-year RFS (%)	P-value with log rank
Residence			0.05
Urban	43.60 (41.40-54.47)	30.6
Rural	45.70 (43.30-53.67)	14.5
Menopause status			0.09
Premenopausal	52.70 (50.47-58.65)	41.7
Postmenopausal	46.50 (44.54-56.72)	25.3
Body mass index (kg/m2)			0.004
< 18.5	60.60 (58.30-68.60)	44.0
18.5-24.9	51.60 (49.20-60.50)	38.0
25.0-29.9	43.90 (42.40-52.90)	33.5
≥ 30.0	37.60 (35.90-44.80)	26.0
Comorbidity			0.05
No	58.67 (53.84-64.00)	33.6
Yes	48.07 (46.60-54.39)	13.9
Stage of breast cancer			0.04
I	68.96 (63.30-74.63)	89.6
II	58.70 (55.25-62.18)	39.5
III	50.90 (48.30-55.47)	21.2
Histology grade			0.02
Grade I	-	57.2
Grade II	62.76 (56.76-69.53)	33.4
Grade III	51.61 (45.96-58.73)	9.2
Deep surgical margin			0.07
Free	63.60 (59.70-66.80)	55.3
Involved	44.72 (39.74-52.34)	8.7
No. of involved lymph node			0.03
< 2	58.40 (53.47-64.50)	28.2
≥ 2	52.90 (46.60-57.70)	15.3
Tumor size (cm)
≤ 2.5	54.80 (53.20-59.60)	39.5	0.04
2-5	46.00 (42.90-54.20)	13.4
> 5	45.00 (40.90-52.90)	6.7
Hormone therapy			0.01
No	43.34 (40.80-50.60)	34.2
Yes	67.20 (60.80-73.80)	53.5
Lymph node status			0.001
Negative	56.70 (53.80-63.80)	35.7
Positive	42.30 (38.40-51.20)	10.1
Type of surgery			0.3
MRM	44.40 (40.30-49.50)	37.0
Breast-conserving therapy	50.70 (49.70-61.10)	22.0
Adjuvant chemotherapy			0.06
Yes	55.80 (47.50-62.70)	32.6
No	47.20 (51.30-58.50)	25.2
Estrogen receptor			0.05
Positive	56.30 (53.40-63.80)	51.0
Negative	46.70 (40.00-57.70)	44.6

RFS, recurrent-free survival; MRM, modified radical mastectomy.